** Drug developer ARS Pharmaceuticals' SPRY.O shares rise 18.8% to $13.84
** Co reports Q4 net income of $49.9 million vs. loss estimate of $14.4 million, according to data compiled by LSEG
** Co posts Q4 revenue of $86.6 million, beating analysts' estimates of $15.8 million
** Profit boosted by partnership revenue from drug developer ALK-Abelló to commercialise allergic reaction nasal spray, neffy, in Europe, Canada and outside of U.S.
** SPRY received a non-refundable, upfront cash payment of $145 million from ALK and, of the total cash payment, $73.5 million was included in SPRY's Q4 revenue
** Up to last close, SPRY had risen 37.7% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.